- Conditions
- Norovirus Infections
- Interventions
- VXA-G1.1-NN, VXA-G2.4-NS, VXA G1.1 NN-T, VXA G2.4 NS-T
- Biological
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 299
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Physical Activity, Overweight or Obesity, Cancer
- Interventions
- Physical Activity Goals mHealth Intervention, TYPE/CONTEXT enhancement, SAVOR enhancement
- Behavioral
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 85
- States / cities
- Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more
- Conditions
- HIV (Human Immunodeficiency Virus)
- Interventions
- MGD020, MGD014, Vorinostat, Temporary treatment interruption
- Drug · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Not listed
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Major Depression
- Interventions
- venlafaxine (Effexor), placebo
- Drug · Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 1998
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Primary Myelofibrosis, Secondary Myelofibrosis, Myeloid Malignancies
- Interventions
- Imetelstat
- Drug
- Lead sponsor
- Geron Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hutchinson-Gilford Progeria Syndrome
- Interventions
- Progerinin, Lonafarnib
- Drug
- Lead sponsor
- PRG Science & Technology Co., Ltd.
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Social Anhedonia, Social Function Impairment
- Interventions
- Behavioral Activation (BA), Supportive Care Therapy (SCT)
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- B-precursor Acute Lymphoblastic Leukemia
- Interventions
- Blinatumomab, Current Wearable Heatlth Monitoring System (CWHMS)
- Drug · Device
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 12
- States / cities
- Duarte, California • Los Angeles, California • Orange, California + 9 more
- Conditions
- Type 2 Diabetes Mellitus, Hypoglycemia
- Interventions
- Continuing Glucose Monitor System
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Pain, Osteoarthritis, Knee, Osteoarthritis, Hip
- Interventions
- Nurse-led Mindfulness Based Intervention, Nurse-led Pain Psychoeducation
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III
- Interventions
- pNGVL4aCRTE6E7L2
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2029
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Baltimore, Maryland
- Conditions
- Sickle Cell Disease
- Interventions
- Voxelotor
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 34
- States / cities
- Little Rock, Arkansas • Oakland, California • Miami, Florida + 20 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- PID control algorithm, MPC control algorithm
- Device
- Lead sponsor
- Sansum Diabetes Research Institute
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Santa Barbara, California
- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- Best Practice Alert
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Amyloid Cardiomyopathy, Transthyretin-Related
- Interventions
- Acoramidis (AG10)
- Drug
- Lead sponsor
- Eidos Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 21 more
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- DCSZ11, Pembrolizumab, Doxorubicin, Tebentafusp
- Drug
- Lead sponsor
- DynamiCure Biotechnology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 11 more
- Conditions
- Anorexia Nervosa, Obsessive-Compulsive Disorder, Social Phobia, Depression, Anxiety
- Interventions
- Radically Open Dialectical Behavior Therapy (RO DBT)
- Behavioral
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 13 Years to 21 Years · Female only
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Diabetes Mellitus
- Interventions
- Onyx BG Meter / App System
- Device
- Lead sponsor
- Ascensia Diabetes Care
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Escondido, California
- Conditions
- Anesthesia
- Interventions
- SafeLM as a supraglottic airway device with video capability, SafeLM as a supraglottic airway device without video capability, SafeLM as a conduit for intubation using an endotracheal tube with video capability, SafeLM as a conduit for intubation using a bougie with video capability
- Device
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Fabry Disease
- Interventions
- PRX-102 1 mg/kg every two weeks
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Iowa City, Iowa + 3 more
- Conditions
- Familial Partial Lipodystrophy
- Interventions
- volanesorsen, Placebo
- Drug
- Lead sponsor
- Akcea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 6
- States / cities
- Ann Arbor, Michigan • Rochester, Minnesota • St Louis, Missouri + 3 more
- Conditions
- Ulcerative Colitis
- Interventions
- Etrolizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,822 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • La Jolla, California • Orange, California + 51 more